Examkin

Soru

Zorluk: ZorSchizophrenia and Psychotic Disorders

A 23-year-old man is evaluated in the psychiatric outpatient clinic for ongoing management of schizophrenia. His symptoms began seven months ago with persistent auditory hallucinations, persecutory delusions, and severe social withdrawal. He has no significant past medical history, and his initial physical examination, comprehensive metabolic panel, and urine toxicology were unremarkable. The psychiatric care team is establishing a comprehensive, long-term psychopharmacological management plan. Arrange the following clinical steps in the most appropriate standard sequence for the pharmacological management of this patient, assuming he consistently demonstrates an inadequate clinical response to each successive intervention despite appropriate time for titration.

  1. 1Initiation of a first-line oral second-generation antipsychotic (e.g., risperidone) at a therapeutic dose.
  2. 2Assessment of medication adherence and optimization of the initial antipsychotic dosage.
  3. 3Cross-titration to a second, different oral antipsychotic agent (e.g., olanzapine).
  4. 4Initiation of clozapine monotherapy with mandatory absolute neutrophil count monitoring.
  5. 5Augmentation therapy with a second antipsychotic, a mood stabilizer, or electroconvulsive therapy (ECT).

Cevap

The correct chronological sequence for managing treatment-resistant schizophrenia is: 1) Initiate a first-line antipsychotic, 2) Verify adherence and optimize the initial dose, 3) Trial a second antipsychotic, 4) Initiate clozapine, and 5) Augment clozapine therapy.
The standard pharmacological management of schizophrenia utilizes a stepwise algorithm designed to balance clinical efficacy with adverse effect profiles. The protocol begins with initiating a standard first- or second-generation antipsychotic. If the patient demonstrates a poor clinical response after 4 to 6 weeks, the physician must first assess medication adherence and ensure the current dosage is optimized before abandoning the trial, as non-adherence is incredibly common. If non-response is firmly confirmed despite adherence, a second trial with a completely different antipsychotic is indicated. Should the patient fail this second adequate trial, they formally meet the criteria for treatment-resistant schizophrenia, establishing clozapine monotherapy as the gold-standard next step. Finally, if the patient exhibits a partial or poor response to an optimized clozapine trial, advanced augmentation strategies (such as adding a second antipsychotic, a mood stabilizer, or utilizing electroconvulsive therapy) are employed.

Adım Adım Çözüm

1
Identify the starting point for first-episode psychosis.
Initiation of a first-line oral second-generation antipsychotic.
A standard antipsychotic trial is the primary intervention and standard of care for a new diagnosis of schizophrenia.
2
Determine the immediate next step upon poor initial response.
Assessment of medication adherence and dose optimization.
Non-adherence is the most common cause of perceived treatment failure in psychiatric populations; it must be completely ruled out before safely switching medications.
3
Determine the management step after a confirmed failure of the first drug.
Cross-titration to a second, different oral antipsychotic agent.
Failure of one antipsychotic warrants a trial of a different agent to evaluate responsiveness before considering the patient fully treatment-resistant.
4
Identify the standard management for treatment-resistant schizophrenia.
Initiation of clozapine monotherapy.
Treatment resistance is strictly defined as the failure of at least two adequate antipsychotic trials, making clozapine the gold-standard drug of choice at this stage.
5
Determine the final step for clozapine-refractory symptoms.
Augmentation therapy with ECT or another psychiatric agent.
When an optimized clozapine monotherapy trial fails, augmentation strategies represent the last line of evidence-based pharmacological treatment.

Anahtar Kavram

Pharmacological management algorithm for schizophrenia and definition of treatment resistance
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Schizophrenia and Psychotic Disorders

Bu konudan daha fazla soru